{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:03:04Z","timestamp":1782284584645,"version":"3.54.5"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1097\/md.0000000000001822","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T12:48:26Z","timestamp":1445690906000},"page":"e1822","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis"],"prefix":"10.1097","volume":"94","author":[{"given":"Liqing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-69-20210309","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ctrv.2010.04.003","article-title":"Metastasis and bone loss: advancing treatment and prevention.","volume":"36","author":"Coleman","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"R3-69-20210309","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy.","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"R4-69-20210309","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Med Care"},{"issue":"suppl 10","key":"R5-69-20210309","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.seminoncol.2004.07.024","article-title":"Bisphosphonate in the treatment of skeletal metastases.","volume":"31","author":"Conte","year":"2004","journal-title":"Semin Oncol"},{"key":"R6-69-20210309","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1677\/erc.0.0110207","article-title":"The role of bisphosphonates in breast and prostate cancers.","volume":"11","author":"Brown","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"R7-69-20210309","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10147-007-0726-2","article-title":"Treatment of breast cancer with bone metastasis: bisphosphonate treatmentcurrent and future.","volume":"13","author":"Kohno","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"R9-69-20210309","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"R10-69-20210309","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"R11-69-20210309","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"R12-69-20210309","first-page":"885","article-title":"Clinical research on zoledronic acid for injection in treatment of the pain of osteolytic osseous metastasis caused by malignancy.","volume":"32","author":"Sun","year":"2005","journal-title":"Chin J Clin Oncol"},{"key":"R13-69-20210309","first-page":"214","article-title":"A clinical study for zoledronic acid in the relief of pain due to metastatic bone malignancy.","volume":"14","author":"Zheng","year":"2005","journal-title":"Chin J New Drugs"},{"key":"R14-69-20210309","first-page":"1011","article-title":"Zoledronic acid in the treatment of malignancy patients with bone metastases: a study of clinical effect and safety.","volume":"13","author":"Chen","year":"2006","journal-title":"Chin J Cancer Prev Treat"},{"key":"R15-69-20210309","first-page":"571","article-title":"Clinical study of zoledronic acid for pain control in bone metastatic cancer.","volume":"13","author":"Li","year":"2006","journal-title":"Chin J Clin Oncol Rehab"},{"key":"R16-69-20210309","first-page":"1169","article-title":"Double- blind and double dim comparative studies on zoledronic acid and pamidronate disodium: phase II trials from 12 centers for treating bone metastasis pain.","volume":"33","author":"Ren","year":"2006","journal-title":"Chin J Clin Oncol"},{"key":"R17-69-20210309","first-page":"180","article-title":"Clinical observation of zometa for pain relief in metastatic bone cancer.","volume":"25","author":"Wang","year":"2006","journal-title":"J Wannan Med College"},{"key":"R18-69-20210309","first-page":"293","article-title":"The clinical study of zoledronic acid in treating metastatic bone pain of malignancy.","volume":"11","author":"Zhou","year":"2006","journal-title":"Lingnan J Emerg Med"},{"key":"R19-69-20210309","first-page":"402","article-title":"Short-term efficacy and side effects of zoledronic acid and pamidronate therapy for the pain of bone metastases from breast cancer.","volume":"2","author":"Liu","year":"2008","journal-title":"Chin J Breast Dis"},{"key":"R20-69-20210309","first-page":"707","article-title":"Clinical comparative study of zoledronic acid versus pamidronate disodium in the treatment of pain of skeletal metastases lung cancer.","volume":"15","author":"Shi Xun, Teng","year":"2008","journal-title":"Chin J Cancer Prev Treat"},{"key":"R21-69-20210309","first-page":"1194","article-title":"Efficacy of zoledronic acid injection on relief of pain due to osseous metastasis.","volume":"18","author":"Li","year":"2010","journal-title":"Mod Oncol"},{"key":"R22-69-20210309","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4103\/0973-1075.92338","article-title":"A randomized controlled trial to compare the efficacy of bisphosphonates in the management of painful bone metastasis.","volume":"17","author":"Choudhury","year":"2011","journal-title":"Indian J Palliat Care"},{"key":"R23-69-20210309","first-page":"1179","article-title":"Comparison study of clinical effect and safety of zoledronic acid versus pamidronate disodiumin in the treatment of pain of skeletal metastases lung cance.","volume":"38","author":"Zhao","year":"2011","journal-title":"Mod Prev Med"},{"key":"R24-69-20210309","first-page":"23","article-title":"Comparison of the efficacy and safety in zoledronic acid, sodium ibandronate and pamidronate disodium in treating nonsmall-cell lung cancer patients with bone metastasis.","volume":"33","author":"Li","year":"2012","journal-title":"Med Philos"},{"key":"R25-69-20210309","first-page":"467","article-title":"Efficacy of pamidronate versus zoledronic acid in reducing skeletal complications in patients with breast cancer.","volume":"33","author":"Yang","year":"2012","journal-title":"Sichuan Med J"},{"key":"R26-69-20210309","first-page":"57","article-title":"Analysis of the effect of three kinds of bisphosphonates for pain of bone metastasis of malignant tumor cost.","volume":"10","author":"An","year":"2013","journal-title":"Med Innovation China"},{"key":"R27-69-20210309","first-page":"59","article-title":"The comparison analysis of zoledronic acid and pamidronate in the treatment of malignant bone metastasis pain.","volume":"26","author":"Cao","year":"2013","journal-title":"J Basic Clin Oncol"},{"key":"R28-69-20210309","first-page":"2718","article-title":"Zoledronic acid and pamidronate disodium in the treatment of bone metastasis of lung cancer: comparison study of short-term efficacy and cost-effectiveness.","volume":"22","author":"Li","year":"2014","journal-title":"Mod Oncol"},{"key":"R31-69-20210309","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer.","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"R32-69-20210309","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis.","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"R33-69-20210309","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1677\/ERC-09-0012","article-title":"Mechanisms of bone metastases of breast cancer.","volume":"16","author":"Suva","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"R34-69-20210309","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","article-title":"Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.","volume":"100","author":"Ottewell","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R35-69-20210309","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","article-title":"Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5-(beta,gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.","volume":"12","author":"Frith","year":"1997","journal-title":"J Bone Miner Res"},{"key":"R36-69-20210309","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/mol.61.5.1255","article-title":"Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADPATP translocase by a nonhydrolyzable, adenine-containing metabolite.","volume":"61","author":"Lehenkari","year":"2002","journal-title":"Mol Pharmacol"},{"key":"R37-69-20210309","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","article-title":"Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.","volume":"264","author":"van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"R38-69-20210309","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogencontaining biphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras.","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000001822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:52:19Z","timestamp":1620960739000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201510030-00069"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":34,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000001822","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}